ClinicaliQ Trial Snapshot
- ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter’s Syndrome or Prolymphocytic Leukemia — Active Not Recruiting • Phase I / Phase II • NCT02029443.
- A new blood cancer drug (acalabrutinib) is being tested for safety and effectiveness in treating chronic lymphocytic leukaemia.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia Interventions: Acalabrutinib Lead Sponsor: Acerta Pharma BV Planned Enrollment: 306 participants